

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 317/22, 317/24, 317/46, 311/29, 311/51, 311/49, C07F 9/30, 9/36, A61K 31/10, 31/18, 31/66		A1	(11) International Publication Number: WO 96/13483 (43) International Publication Date: 9 May 1996 (09.05.96)
(21) International Application Number: PCT/CA95/00601 (22) International Filing Date: 24 October 1995 (24.10.95) (30) Priority Data: 330,172 27 October 1994 (27.10.94) US (60) Parent Application or Grant (63) Related by Continuation US 330,172 (CON) Filed on 27 October 1994 (27.10.94) (71) Applicant (for all designated States except US): MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): ATKINSON, Joseph, G. [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). WANG, Zhaoyin [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA).		(74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA). (81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published With international search report. With amended claims.	

(54) Title: STILBENE DERIVATIVES USEFUL AS CYCLOOXYGENASE-2 INHIBITORS**(57) Abstract**

The invention encompasses novel compounds of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION

STILBENE DERIVATIVES USEFUL AS CYCLOOXYGENASE-2 INHIBITORS

5 BACKGROUND OF THE INVENTION


This invention relates to compounds and pharmaceutical compositions for the treatment of cyclooxygenase mediated diseases and methods of treatment thereof.

Non-steroidal, antiinflammatory drugs exert most of their
10 antiinflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Up until recently, only one form of cyclooxygenase had been characterized, this corresponding to cyclooxygenase-1 or the constitutive
15 enzyme, as originally identified in bovine seminal vesicles. Recently the gene for a second inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized from chicken, murine and human sources. This enzyme is distinct from the cyclooxygenase-1 which has now also been cloned, sequenced and characterized from
20 sheep, murine and human sources. The second form of cyclooxygenase, cyclooxygenase-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, we have concluded that the constitutive enzyme, cyclooxygenase-1, is
25 responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, cyclooxygenase-2, is mainly responsible for the pathological effects of prostaglandins where
30 rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of cyclooxygenase-2 will have similar antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced


- 2 -

- uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects. In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.

A number of stilbene derivatives are known in the chemical literature. Toda *et al.*, in *Chem. Commun.* 1234-5 (1984) describe the dialdehydes A and the diol B is described by Tsuji *et al.*, *J. Am. Chem. Soc.* 88, 1289-92 (1966), and diol C was prepared by Dhawau *et al.*, *J. Org. Chem.*, 45, 922-4 (1980). No utility is disclosed for these compounds, nor do they carry the R¹ substituent of the present invention.




A
X = H or Cl



B X = H Tsuji
C X = Cl Dhawan

- Structure D is disclosed as having usefulness for treating hyperlipidemia by Hashimoto *et al.*, European Patent Application 424,541 (May 2, 1991).



X, Y are halogen

R is C₁₋₆ alkyl

n is 0, 1 or 2


D

- 3 -

These compounds (D) lack the second carbon substituent X of the present invention and have an unrelated utility.

SUMMARY OF THE INVENTION

5 The invention encompasses novel compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.




I

10 The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.

- 4 -

DETAILED DESCRIPTION OF THE INVENTION

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases



5

I

or pharmaceutically acceptable salts thereof wherein

X is

10

- (a) CH₂OH,
- (b) CHO, or
- (c) CO₂R⁴,

Y is

15

- (a) CH₂OH, or
- (b) CH₂OCOR⁵,

R¹ is selected from the group consisting of

20

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)(NH)CH₃,
- (e) S(O)(NH)NH₂,
- (f) S(O)(NH)NHC(O)CF₃,
- (g) P(O)(CH₃)OH, and
- (h) P(O)(CH₃)NH₂;

25

R² and R³ each are independently selected from the group consisting of

- 5 -

- 5 (a) hydrogen,
(b) halo,
(c) C₁-6alkoxy,
(d) C₁-6alkylthio,
(e) CN,
(f) CF₃,
(g) C₁-6alkyl,
(h) N₃;

10 R⁴ is selected from the group consisting of

- (a) hydrogen, and
(b) C₁-6alkyl;

R⁵ is selected from the group consisting of

- 15 (a) hydrogen,
(b) C₁-6alkyl,
(c) mono- or disubstituted phenyl wherein the substituent is
selected from
20 (1) hydrogen,
(2) halo,
(3) C₁-6alkyl,
(4) C₁-6alkoxy,
(5) C₁-6alkylthio,
(6) OH,
25 (7) CN,
(8) CF₃,
(9) CO₂R⁴.

A preferred genus of compounds of Formula I is that

30 wherein:

Y is CH₂OH or CH₂OCOR⁵;

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,

- 6 -

- (b) $\text{S(O)}_2\text{NH}_2$,
(c) $\text{S(O)}_2\text{NHC(O)CF}_3$,
(d) S(O)NHCH_3 ,
(e) S(O)NHNH_2 , and
5 (f) S(O)NHNHC(O)CF_3 ;

R^2 and R^3 are each independently selected from the group consisting of

- (a) hydrogen,
(b) fluoro, chloro, and bromo,
(c) C_{1-4} alkoxy,
10 (d) C_{1-4} alkylthio,
(e) CN,
(f) CF_3 ,
(g) C_{1-4} alkyl, and
(h) N_3 .

15

Within this sub-genus is the class of compounds of Formula

I wherein:

R^2 and R^3 are each independently selected from the group consisting of

- (1) hydrogen, and
20 (2) halo;

R^4 is hydrogen; and

R^5 is C_{1-6} alkyl.

25 This group may be more particularly defined as the
compounds of Formula I wherein

R^1 is selected from the group consisting of

- (a) $\text{S(O)}_2\text{CH}_3$, and
(b) $\text{S(O)}_2\text{NH}_2$;

30 R^2 and R^3 are each independently selected from the group consisting of

- (1) hydrogen,
(2) halo, selected from the group consisting of fluoro,
chloro and bromo.

- 7 -

Another preferred genus of compounds of Formula I is that

wherein:

X is CO_2R^4 ,

Y is CH_2OCOR^5 ,

5 R^1 is $\text{S}(\text{O})_2\text{CH}_3$,

R^2 and R^3 each are independently selected from the group consisting of

(a) hydrogen, and

(b) halo,

R^4 is selected from the group consisting of

10 (a) hydrogen, and

(b) C_1 -6alkyl,

R^5 is selected from the group consisting of

(a) C_1 -6alkyl,

15 (b) mono- or disubstituted phenyl wherein the substituent is selected from

(1) hydrogen,

(2) halo,

(3) C_1 -6alkoxy, and

(4) OH.

20

For purposes of this specification alkyl is defined to include linear, branched, and cyclic structures, with C_1 -6alkyl including including methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and
25 cyclohexyl. Similarly, C_1 -6alkoxy is intended to include alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic configuration. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like. Likewise, C_1 -6alkylthio is intended to include alkylthio groups of
30 from 1 to 6 carbon atoms of a straight, branched or cyclic configuration. Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies $-\text{SCH}_2\text{CH}_2\text{CH}_3$.

- 8 -

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

In a second embodiment, the invention encompasses
5 pharmaceutical compositions for inhibiting cyclooxygenase and for treating cyclooxygenase mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.

10 Within this embodiment the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase-2 and for treating cyclooxygenase-2 mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described
15 above.

In a third embodiment, the invention encompasses a method of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases, advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 as disclosed herein comprising:
20 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I as disclosed herein.

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a
25 pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases
30 include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary,

- 9 -

and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
5 ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

10 It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

The Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic
15 fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following
20 surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer. Compounds of Formula I may also be useful for the treatment of dementia including pre-senile and senile dementia, and in particular, dementia associated with Alzheimer
25 Disease (i.e. Alzheimer's dementia).

Compounds of Formula I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma. They will also be useful to
30 inhibit bone loss (osteoporosis).

By virtue of its high cyclooxygenase-2 (COX-2) activity and/or its selectivity for cyclooxygenase-2 over cyclooxygenase-1 (COX-1) as defined above, compounds of Formula I will prove useful as an alternative to conventional non-steroidal antiinflammatory drugs

- 10 -

(NSAID'S) particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (e.g. impaired renal function); those prior to surgery or taking anticoagulants; and those susceptible to NSAID induced asthma.

Similarly, compounds of Formula I, will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dexamethorphan; a diuretic; a sedating or non-sedating antihistamine. In addition the invention encompasses a method of treating cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effect amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

Compounds of the present invention are inhibitors of cyclooxygenase-2 and are thereby useful in the treatment of cyclooxygenase-2 mediated diseases as enumerated above. This activity is illustrated by their ability to selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Accordingly, in one assay, the ability of the

- 11 -

compounds of this invention to treat cyclooxygenase mediated diseases can be demonstrated by measuring the amount of prostaglandin E₂ (PGE₂) synthesized in the presence of arachidonic acid, cyclooxygenase-1 or cyclooxygenase-2 and a compound of Formula I. The IC₅₀ values
5 represent the concentration of inhibitor required to return PGE₂ synthesis to 50% of that obtained as compared to the uninhibited control.

Illustrating this aspect, we have found that the Compounds of the Examples are more than 100 times more effective in inhibiting COX-2 than they are at inhibiting COX-1. In addition they all have a COX-2
10 IC₅₀ of 1 nM to 1 μ M. By way of comparison, Ibuprofen has an IC₅₀ for COX-2 of 1 μ M, and Indomethacin has an IC₅₀ for COX-2 of approximately 100 nM. For the treatment of any of these cyclooxygenase mediated diseases, compounds of Formula I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit
15 formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of
20 humans.

As indicated above, pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined may optionally include one or more ingredients as listed above.

25 The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any
30 method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the

- 12 -

active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The

- 13 -

aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

5 Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth
10 above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active
15 ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

20 The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin,
25 and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

30 Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This

- 14 -

suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-
5 acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be
10 employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-
15 irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed.
20 (For purposes of this application, topical application shall include mouth washes and gargles.)

Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per
25 patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day, preferably 2.5 mg to 1 g per patient per day.

The amount of active ingredient that may be combined with
30 the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary

- 15 -

from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

5 It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

10

Methods of Synthesis


The compounds of the present invention can be prepared according to the following methods.

- 16 -


Method A:

A diphenyl lactone 2 is reduced to the diol 1a by a suitable reducing agent such as diisobutyl aluminum hydride or lithium aluminum hydride in an appropriate solvent such as toluene, hexane, tetrahydro-
5 furan or ether. The diol is acylated with an anhydride or an acid chloride in the presence of a base such as pyridine, triethylamine or aqueous sodium hydroxide. This acylation gives rise to the desired isomer 1b and the undesired isomer 3, which are separated by chromatography or crystallization. Compound 1b is oxidized to the aldehyde 1c by a reagent
10 such as manganese dioxide. Mild acid or base hydrolysis of 1c gives 1d which is in equilibrium with lactol form 4. Alternatively, 1c can be oxidized with Cr+6 reagents to acid 1e. Base treatment of 1e generates the salt 1f. Esters 1g can be prepared by reacting 1e with an alkylating agent in the presence of a base. The methyl ester of 1e is conveniently
15 prepared on a small scale by the reaction of 1e with diazomethane in ether.

- 17 -

METHOD A


- 18 -

METHOD A CONTINUED

- 19 -

Method AA:

A diphenyl maleic anhydride 18 can be reduced to diol 1a with suitable hydride reducing agents such as di-isobutyl aluminum hydride or lithium aluminum hydride. Solvents such as toluene, tetrahydrofuran or ether, or a mixture thereof are suitable for the reduction.

METHOD AA


The lactones 2 are prepared by the following methods.

Method B:

15 An appropriately substituted aryl bromomethyl ketone 5 is reacted with an appropriately substituted aryl acetic acid 6 in a solvent such as acetonitrile in the presence of a base such as triethylamine and then treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to afford the lactone 2.



20

- 20 -

METHOD B5 Method C


By reacting an acetylene 7 with carbon monoxide and water in the presence of suitable catalysts, a mixture of Compound 2 and its isomer 8 is obtained. The isomers are separable by standard procedures in the art such as chromatography or crystallization. Examples of useful catalysts and conditions are PdCl₂ in aqueous HCl and EtOH, heated at 50-150°C and 50-150 atmospheres of pressure, or Rh₄(CO)₁₂ (or Rh₆(CO)₁₆) in aqueous THF (or acetone, acetonitrile, benzene, toluene, EtOH, MeOH) containing a trialkylamine, at 50-150°C and 20-300 atmospheres pressure. See Takahashi *et al.*, *Organometallics* **1991**, *10*, 2493-2498; and Tsuji *et al.*, *J. Am. Chem. Soc.* **1966**, *88*, 1289-1292.

- 21 -

METHOD C5 Method D

- 1, 4-Addition to **2** of 4-methylthiophenyl organometallic reagents **10** in the presence of copper salts and the trapping of the resultant enolate with trialkyl silyl chloride such as TMSCl or TIPSCl provide the ketene acetal **11**. The ketene acetal can then be oxidized to the substituted butenolide **12** by the method of Ito using catalytic amounts of Pd₂(OAc)₂ and Cu(OAc)₂ and O₂ in MeOH or by the method of Magnus using PhIO/TMSN₃ and Bu₄NF. Introduction of the iodine can be accomplished by treating **13** with I₂ in the presence of pyridine to afford **13**. Palladium catalyzed Suzuki or Stille coupling of **13** with the appropriate aryl partner such as the boronic acid **14** provides the butenolide **15**. The sulfide can be oxidized to a sulfone by various oxidizing agents such as peracetic acid, MPPM, MMPP or H₂O₂ to give the desired Compound **2a**. See Y. Ito *et al.*, *J. Am. Chem. Soc.* **1979**, 101, 494, footnote 2, and P. Magnus *et al.*, *Tet. Lett.* **1992**, 2933.

- 22 -

METHOD D


- 23 -

Method E


The 2,3-diphenyl maleic anhydride 18 can be prepared by the method of Fields [*J. Org. Chem.*, vol. 55, pp. 5165-70 (1990); US 4,596,867] in which a phenylacetic acid 16 is made to react with an α -oxophenylacetic acid 17 (preferably as its potassium salt) in refluxing acetic anhydride.

A multi-step sequence to 18 from phenylacetonitriles such as 19 and 20 is described by Smith, et. al., in *J. Org. Chem.*, vol. 55, pp. 3351-62 (1990).

Florac and co-workers in *Tetrahedron*, vol. 46, pp. 445-52 (1990) describe another synthesis of 18 in several steps from α -bromo phenylaceto hydrazides 21 and 22.



- 24 -






Representative Compounds

In Table I are shown some lactones **2** from which the compounds of the present invention can be prepared according to Method A.

In Table II and III are shown compounds representative of the present invention (structures Ia and Ib).





- 25 -

TABLE I

	Lactone
 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)OCC2)c3ccccc3</chem>	1
 <chem>NS(=O)(=O)c1ccc(cc1)C2=C(C(=O)OCC2)c3ccc(F)cc3</chem>	2
 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)OCC2)c3cc(F)cc(F)c3</chem>	3






- 26 -

TABLE 1 (CONTINUED)

		Lactone
	4	
	5	
	6	
	7	






- 27 -

TABLE 1 (CONTINUED)

	Lactone
	8
	
	9
	
	10
	
	11
	
	12






- 28 -

TABLE 1 (CONTINUED)

	Lactone
	13
	14
	15
	16
	17






- 29 -

TABLE I (CONTINUED)

Lactone	
	18
	19
	20
	21
	22






- 30 -

TABLE I (CONTINUED)

		Lactone
	23	
	24	
	25	
	26	
	27	





- 31 -

TABLE I (CONTINUED)

Lactone	
28	
29	
30	
31	
32	





- 32 -

TABLE I (CONTINUED)

		Lactone
	33	
	34	
	35	
	36	





- 33 -

TABLE I (CONTINUED)

	Lactone
	37
	38
	39
	40

- 34 -


TABLE I (CONTINUED)

	Lactone
	41
	42
	43
	44


- 35 -

TABLE I (CONTINUED)


Lactone



45




46



47


- 36 -

TABLE II

Ia

<u>Compound</u>	<u>R²</u>	<u>R³</u>	<u>Y</u>	<u>X</u>
1	H	H	CH ₂ OH	CH ₂ OH
2	H	H	CH ₂ OH	CH ₂ OAc
3	H	H	CHO	CH ₂ OAc
4	H	H	CO ₂ H	CH ₂ OAc
5	H	H	CO ₂ Me	CH ₂ OAc
6	H	H	CH ₂ OH	CH ₂ OCOPh
7	H	H	CHO	CH ₂ OCOPh
8	H	H	CO ₂ H	CH ₂ OCOPh
9	H	H	CO ₂ Me	CH ₂ OCOPh
10	F	F	CH ₂ OH	CH ₂ OH
11	F	F	CH ₂ OH	CH ₂ OAc
12	F	F	CHO	CH ₂ OAc
13	F	F	CO ₂ H	CH ₂ OAc
14	F	F	CO ₂ Me	CH ₂ OAc
15	H	F	CH ₂ OH	CH ₂ OH
16	H	F	CH ₂ OH	CH ₂ OAc
17	H	F	CHO	CH ₂ OAc
18	H	F	CO ₂ H	CH ₂ OAc
19	H	F	CO ₂ Me	CH ₂ OAc

- 37 -

TABLE III

Ib

<u>Compound</u>	<u>R²</u>	<u>R³</u>	<u>Y</u>	<u>X</u>
20	H	H	CH ₂ OH	CH ₂ OH
21	H	H	CH ₂ OH	CH ₂ OAc
22	H	H	CHO	CH ₂ OAc
23	H	H	CO ₂ H	CH ₂ OAc
24	H	H	CO ₂ Me	CH ₂ OAc
25	H	H	CH ₂ OH	CH ₂ OCOPh
26	H	H	CHO	CH ₂ OCOPh
27	H	H	CO ₂ H	CH ₂ OCOPh
28	H	H	CO ₂ Me	CH ₂ OCOPh
29	F	F	CH ₂ OH	CH ₂ OH
30	F	F	CH ₂ OH	CH ₂ OAc
31	F	F	CHO	CH ₂ OAc
32	F	F	CO ₂ H	CH ₂ OAc
33	F	F	CO ₂ Me	CH ₂ OAc
34	H	F	CH ₂ OH	CH ₂ OH
35	H	F	CH ₂ OH	CH ₂ OAc
36	H	F	CHO	CH ₂ OAc
37	H	F	CO ₂ H	CH ₂ OAc
38	H	F	CO ₂ Me	CH ₂ OAc

- 38 -

Assays for Determining Biological Activity

The compound of Formula I can be tested using the following assays to determine their cyclooxygenase-2 inhibiting activity.

5 Inhibition of Cyclooxygenase Activity

Compounds are tested as inhibitors of cyclooxygenase activity in whole cell and microsomal cyclooxygenase assays. Both of these assays measure prostaglandin E₂ (PGE₂) synthesis in response to arachidonic acid, using a radioimmunoassay. Cells used for whole cell
10 assays, and from which microsomes are prepared for microsomal assays, are human osteosarcoma 143 cells (which specifically express cyclooxygenase-2) and human U-937 cells (which specifically express cyclooxygenase-1). In these assays, 100% activity is defined as the difference between prostaglandin E₂ synthesis in the absence and
15 presence of arachidonate addition. IC₅₀ values represent the concentration of putative inhibitor required to return PGE₂ synthesis to 50% of that obtained as compared to the uninhibited control.

Representative Rat Paw Edema Assay – Protocol

Male Sprague-Dawley rats (150-200 g) are fasted overnight
20 and are given p.o., either vehicle (5% tween 80 or 1% methocell) or a test compound, at 9 - 10 a.m. One hr later, a line is drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (V_{0h}) is measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water
25 displacement. The animals are then injected subplantarily with 50 ul of a 1% carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e. 500 ug carrageenan per paw). Three hr later, the paw volume (V_{3h}) is measured and the increases in paw volume (V_{3h} - V_{0h}) are calculated. The animals are
30 euthanized by CO₂ aphyxiation and the absence or presence of stomach lesions scored. Stomach scores are expressed as the sum of total lesions in mm. Paw edema data are compared with the vehicle-control group and percent inhibition calculated taking the values in the control group as 100%. All treatment groups are coded to eliminate observer bias.

- 39 -

NSAID-Induced Gastropathy In Rats

Rationale

5 The major side effect of conventional NSAIDs is their
ability to produce gastric lesions in man. This action is believed to be
caused by inhibition of Cox-1 in the gastrointestinal tract. Rats are
particularly sensitive to the actions of NSAIDs. In fact, rat models have
been used commonly in the past to evaluate the gastrointestinal side
effects of current conventional NSAIDs. In the present assay, NSAID-
10 induced gastrointestinal damage is observed by measuring fecal ^{51}Cr
excretion after systemic injection of ^{51}Cr -labeled red blood cells. Fecal
 ^{51}Cr excretion is a well-established and sensitive technique to detect
gastrointestinal integrity in animals and man.

15 Methods

Male Sprague-Dawley rats (150-200 g) are administered
orally a test compound either once (acute dosing) or b.i.d. for 5 days
(chronic dosing). Immediately after the administration of the last dose,
the rats are injected via a tail vein with 0.5 mL of ^{51}Cr -labeled red blood
20 cells from a donor rat. The animals are placed individually in
metabolism cages with food and water *ad lib*. Feces are collected for a
48 hr period and ^{51}Cr fecal excretion is calculated as a percent of total
injected dose. ^{51}Cr -labeled red blood cells are prepared using the
following procedures. Ten mL of blood is collected in heparinized tubes
25 via the vena cava from a donor rat. Plasma is removed by centrifugation
and replenished with an equal volume of HBSS. The red blood cells are
incubated with 400 μCi of sodium ^{51}Cr chromate for 30 min. at 37°C . At
the end of the incubation, the red blood cells are washed twice with 20
mL HBSS to remove free sodium ^{51}Cr chromate. The red blood cells are
30 finally reconstituted in 10 mL HBSS and 0.5 mL of the solution (about 20
 μCi) is injected per rat.

Protein-Losing Gastrophathy in Squirrel Monkeys

- 40 -

Rationale

Protein-losing gastropathy (manifested as appearance of circulating cells and plasma proteins in the GI tract) is a significant and dose-limiting adverse response to NSAIDs. This can be quantitatively assessed by intravenous administration of $^{51}\text{CrCl}_3$ solution. This isotopic ion can avidly bind to cell and serum globins and cell endoplasmic reticulum. Measurement of radioactivity appearing in feces collected for 24 hr after administration of the isotope thus provides a sensitive and quantitative index of protein-losing gastropathy.

Methods

Groups of male squirrel monkeys (0.8 to 1.4 kg) are treated by gavage with either 1% methocell or 5% Tween 80 in H_2O vehicles, (3 mL/kg b.i.d.) or test compounds at doses from 1-100 mg/kg b.i.d. for 5 days. Intravenous ^{51}Cr ($5\mu\text{Ci/kg}$ in 1 mL/kg PBS) is administered 1 hr after the last drug/vehicle dose, and feces collected for 24 hr in a metabolism cage and assessed for excreted ^{51}Cr by gamma-counting. Venous blood is sampled 1 hr and 8 hr after the last drug dose, and plasma concentration of drug measured by RP-HPLC.

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- (i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm. Hg) with a bath temperature of up to 60°C; the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with

- 41 -

different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).

The following abbreviations have the indicated meanings:

Ac	=	acetyl
Bn	=	benzyl
DBU	=	1,8-diazabicyclo[5.4.0]undec-7-ene
DIBAL	=	diisobutylaluminum hydride
DMAP	=	4-(dimethylamino)pyridine
DMF	=	N,N-dimethylformamide
Et ₃ N	=	triethylamine
HBSS	=	Hanks' balanced salt solution
LDA	=	lithium diisopropylamide
m-CPBA	=	metachloroperbenzoic acid
MMPP	=	monoperoxyphthalic acid
MPPM	=	monoperoxyphthalic acid, magnesium salt 6H ₂ O
Ms	=	methanesulfonyl = mesyl = S(O) ₂ Me
MsO	=	methanesulfonate = mesylate

- 42 -

NSAID	=	non-steroidal anti-inflammatory drug
OXONE®	=	2KHSO ₅ •KHSO ₄ •K ₂ SO ₄
PBS	=	phosphate buffered saline
PCC	=	pyridinium chlorochromate
PDC	=	pyridinium dichromate
Ph	=	phenyl
Phe	=	benzenediyl
Pye	=	pyridinediyl
r.t.	=	room temperature
rac.	=	racemic
SAM	=	aminosulfonyl or sulfonamide or S(O) ₂ NH ₂
TBAF	=	tetra-n-butylammonium fluoride
Th	=	2- or 3-thienyl
TFAA	=	trifluoroacetic acid anhydride
THF	=	tetrahydrofuran
Thi	=	thiophenediyl
TLC	=	thin layer chromatography
TMS-CN	=	trimethylsilyl cyanide
Tz	=	1H (or 2H)-tetrazol-5-yl
C ₃ H ₅	=	allyl

Alkyl Group Abbreviations

Me	=	methyl
Et	=	ethyl
n-Pr	=	normal propyl
i-Pr	=	isopropyl
n-Bu	=	normal butyl
i-Bu	=	isobutyl
s-Bu	=	secondary butyl
t-Bu	=	tertiary butyl
c-Pr	=	cyclopropyl
c-Bu	=	cyclobutyl
c-Pen	=	cyclopentyl
c-Hex	=	cyclohexyl

- 43 -

EXAMPLE 1

5 (Z)-2-(4-(METHYLSULFONYL)PHENYL)-3-PHENYL-2-BUTENE-1,4-DIOL

To a solution of DIBAL (75 mL, 1 M in toluene) cooled to 0°C was added dropwise a solution of Lactone 1 (5.0 g in 200 mL of THF). After stirring for 30 min at 0°C and 30 min at r.t., the mixture was then transferred into 200 mL of 1M sodium potassium tartrate containing 50 mL of MeOH via a double-tipped needle. The product was extracted with EtOAc (200 mL) and dried over MgSO₄. Filtration and concentration provided the title compound (5.0 g) as a colorless syrup.

15 Alternative Preparation

To a mixture of 3.28 g (10 mmol) of anhydride 1 and 200 mL of Et₂O is added 0.76 g (20 mmol) of LiAlH₄. The addition is done in portions over a period of 20 min while the reaction mixture is stirred vigorously at r.t. After an additional 30 min, 1N HCl is added, the layers are separated and the aqueous layer is extracted with 200 mL of Et₂O. The combined Et₂O extracts are dried (MgSO₄), evaporated and the residue chromatographed to obtain the title compound.

25 EXAMPLE 2

30 (Z)-2-(4-(METHYLSULFONYL)PHENYL)-3-PHENYL-2-BUTENE-1,4-DIOL 1-ACETATE

A solution of 2-(4-(methylsulfonyl)phenyl)-3-phenyl-2-butene-1,4-diol (149 mg) and Et₃N (0.2 mL) in 20 mL of CH₂Cl₂ was treated with Ac₂O (0.05 mL) and DMAP (5 mg). After stirring for 10 min at r.t., the mixture was concentrated, and the residue was purified by flash chromatography eluted with 3:2 EtOAc/hexane to afford 40 mg of

- 44 -

the title compound as a white solid along with 30 mg of its regioisomer as a syrup.

¹NMR (acetone-d₆) δ 7.70 (2H, d), 7.32 (2H, d), 7.05-7.12 (5H, m), 5.71
5 (2H, s), 4.62 (2H, d), 4.06 (1H, t), 3.05 (3H, s), 1.93 (3H, s).

EXAMPLE 3

10 (Z)-4-ACETOXY-3-(4-(METHYLSULFONYL)PHENYL)-2-PHENYL-2-BUTENAL

A mixture of the acetate from Example 2 (215 mg) and
MnO₂ (1.2 g) in 30 mL of CH₂Cl₂ was stirred for 12 h at r.t., and then
15 filtered through a pad of celite. The filtrate was concentrated to give 160
mg of the title compound as a yellow solid.

¹NMR (acetone-d₆) δ 10.50 (1H, s), 7.78 (2H, d), 7.46 (2H, d), 7.16 (3H,
m), 6.98 (2H, m), 5.60 (2H, s), 3.06 (3H, s), 1.93 (3H, s).
20

EXAMPLE 4

25 (Z)-4-ACETOXY-3-(4-(METHYLSULFONYL)PHENYL)-2-PHENYL-2-BUTENOIC ACID.

To a solution of the aldehyde from Example 3 (160 mg) and
2-methyl-2-butene (6 mL) in 2-methyl-2-propanol (35 mL) was added a
solution of NaClO₂ (1 g) and NaH₂PO₄ (1 g) in 10 mL of H₂O. The
30 mixture was stirred for 2 h at r.t., and concentrated. The residue was then
taken into 50 mL of pH 7 buffer solution (1 M) and extracted with EtOAc
(50 mL). The extract was dried over MgSO₄ and concentrated. The
residue was purified by flash chromatography, eluting with 3:1
EtOAc/hexane containing 1% HOAc to give 150 mg of the title
35 compound as a white solid.

- 45 -

¹NMR (acetone-d₆) δ 7.77 (2H, d), 7.43 (2H, d), 7.10-7.20 (5H, m), 5.25 (2H, s), 3.06 (3H, s), 2.60-3.00 (1H, bs), 1.89 (3H, s).

5

EXAMPLE 5

(Z)-4-ACETOXY-3-(4-(METHYLSULFONYL)PHENYL)-2-PHENYL-2-BUTENOIC ACID, METHYL ESTER.

10

To a suspension of the acid from Example 4 (100 mg) in Et₂O (20 mL) was added dropwise excess CH₂N₂ solution in Et₂O. The solution was concentrated and the solid was swished with 2:1 hexane/EtOAc to give 90 mg of the title compound as a white solid.

15

¹NMR (acetone-d₆) δ 7.79 (2H, d), 7.44 (2H, d), 7.17 (3H, m), 7.08 (2H, m), 5.17 (2H, s), 3.80 (3H, s), 3.06 (3H, s), 1.90 (3H, s).

20

PREPARATION OF MALEIC ANHYDRIDE INTERMEDIATES

ANHYDRIDE 1

2-(4-(Methylsulfonyl)phenyl)-3-phenylmaleic anhydride

25

A mixture of 21.4 g (0.10 mol) of 4-(methylsulfonyl)phenylacetic acid [Forrest, et al., *J. Chem. Soc.* (1948), 1501-1506] and 18.8 g (0.10 mol) of potassium benzoyl formate in 200 mL of Ac₂O is stirred and refluxed for 2 h. The reaction mixture is cooled to r.t. and poured into 1L of H₂O and stirred until the Ac₂O dissolves (ca. 2h). The precipitate is filtered and dried to obtain the title compound. If desired, it is recrystallized from HOAc or acetone.

30

- 46 -

PREPARATION OF LACTONE INTERMEDIATESLACTONE 1

5

PREPARATION A3-Phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

To a solution of phenylacetic acid (27.4 g, 201 mmol) and 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Lactone 11, Step 1) (60 g, 216 mmol, 1.075 eq.) in acetonitrile (630 mL) at 25°C was added slowly Et₃N (30.8 mL, 1.1 eq.). The mixture was stirred for 20 min. at r.t. and then cooled in an ice bath. DBU (60.1 mL, 3 eq.) was slowly added. After stirring for 20 min. in the ice bath, the reaction was complete and the mixture was acidified with 1N HCl (color changes from dark brown to yellow). Then 2.4 L of ice and H₂O were added, stirred for a few minutes, then the precipitate was filtered and rinsed with H₂O (giving 64 g of crude wet product). The solid was dissolved in 750 mL of CH₂Cl₂, dried over MgSO₄, filtered and 300 g of silica gel was added. The solvent was evaporated to near dryness (silica gel a bit sticky) and the residue was applied on top of a silica gel plug in a sintered glass funnel and eluted with 10% EtOAc/CH₂Cl₂, giving after evaporation of the solvent and a swish in EtOAc, 36.6 g (58%) of the title compound.

- 47 -

Analysis calculated for C₁₇H₁₄O₄S
 C, 64.95; H, 4.49; S, 10.20
Found: C, 64.63; H, 4.65; S, 10.44

5

PREPARATION B

3-Phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Into a 20 ml glass ampule are added 1 g of 2-(4-(methylsulfonyl)phenyl)phenylacetylene, 20 mg of Rh₄(CO)₁₂, 1.5 g of Et₃N,
10 10 mL of THF and 1 mL of H₂O under a nitrogen atmosphere, and the ampule is placed in a 100-ml stainless steel autoclave. The reaction system is flushed three times with CO then charged at r.t. to a initial CO pressure of 100 atm. The reaction is kept at 100°C for 5 hr. The solution is then diluted with 50 mL of benzene and washed with brine and 1N
15 HCl. The benzene solution is dried over Na₂SO₄, and concentrated. The crude products are separated by column chromatography on silica gel, eluting with 2:1 EtOAc/hexane to give the title compound and its regioisomer.

20

PREPARATION C

3-Phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

25 Step 1: 2-Trimethylsilyloxy-4-(4-(methylthio)phenyl)-3,4-dihydrofuran

To a solution of 3.86 g (19 mmol) of 4-bromothioanisole in 90 mL of Et₂O cooled at -78°C, is added 22 mL of 1.7 M solution of t-BuLi in pentane (38 mmol) dropwise. The reaction mixture is stirred for 15 min. at -78°C and 3.8 g of CuI is added and the reaction mixture is
30 allowed to warm to -40°C over a period of 30 min. A solution of 1.7 g of 2-(5H)-furanone in 10 mL of THF is added. After stirring for 1 hr, 2 mL of freshly distilled TMSCl is added dropwise. The reaction mixture is then treated with 2 mL of Et₃N and 50 ml of sat. NaHCO₃, and extracted with 100 mL of Et₂O. The Et₂O layer is dried over Na₂SO₄ and

- 48 -

concentrated to the crude title compound which is used for the next step without further purification.

Step 2: 4-(4-(Methylthio)phenyl)-2-(5H)-furanone

5 To a solution of 4 g of Pd(OAc)₂ in 100 ml of acetonitrile is added dropwise the crude product from Step 1 (5 g) under nitrogen at r.t. After 10 hr at r.t., the mixture is concentrated by evaporation and the residue is purified by flash chromatography on silica gel eluted with 2:1 hexane/EtOAc to give the title compound.

10 **Step 3: 3-Iodo-4-(4-(methylthio)phenyl)-2-(5H)-furanone**

To a solution of 3 g of the product of Step 2 in 30 mL of pyridine is added 8.7 g of I₂. The mixture is stirred for 24 hr and then diluted with 200 mL of Et₂O, washed with 100 mL of 5N HCl and 50 mL
15 of 5N Na₂S₂O₃. The Et₂O layer is dried over Na₂SO₄ and concentrated to give the title compound.

Step 4: 3-Phenyl-4-(4-(methylthio)phenyl)-2-(5H)-furanone

A mixture of 4 g of the product of Step 3, 3.7 g of
20 PhB(OH)₂, 0.4 g of Ph₃As, 0.4 g of PdCl₂(PhCN)₂ in 100 mL of benzene and 15 mL of 2N NaOH is refluxed for 6 hr. Et₂O (200 mL) is then added and the mixture is washed with 100 mL of saturated NaHCO₃. The organic layer is dried over MgSO₄ and concentrated. The residue is purified by flash chromatography on silica gel eluted with 4:1
25 hexane/EtOAc to give the title compound.

Step 5: 3-Phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

To a solution of 3 g of the product of Step 4 in 80 mL of 10:1 CH₂Cl₂/MeOH is added 5.5 g of MPPM. The reaction mixture is
30 stirred at r.t. for 2 hr and then diluted with 100 mL of 1:1 hexane/EtOAc. After filtration and concentration, the residue is purified by flash chromatography eluted with 2:1 EtOAc/hexane to give the title product.

- 49 -

LACTONE 23-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone

- 5 ^1H NMR (CD_3COCD_3) δ 5.34 (2H, s), 6.67 (2H, bd), 7.18 (2H, m), 7.46 (2H, m), 7.61 (2H, m), 7.90 (2H, m).
M.P. 187-188°C (d).

LACTONE 3

10

3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

- | | |
|-----------|---|
| Analysis | calculated for $\text{C}_{17}\text{H}_{12}\text{F}_2\text{O}_4\text{S}$ |
| | C, 58.28; H, 3.45; S, 9.15 |
| 15 Found: | C, 58.27; H, 3.50; S, 9.27 |

LACTONE 4

- 20 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
To a solution of 3,4-difluorophenylacetic acid (ALDRICH CHEMICAL) (10 g) and 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Lactone 11, Step 1) (17.3 g) in acetonitrile (200 mL) at r.t. was added slowly Et_3N (20.2 mL). After 1 hr at r.t., the mixture was cooled in an ice bath and treated with 17.4 mL of DBU. After 2 hr at 0°C, the mixture
- 25 was treated with 200 mL of 1N HCl and the product was extracted with EtOAc, dried over Na_2SO_4 and concentrated. The residue was applied on top of a silica gel plug in a sintered glass funnel, eluted with 75% EtOAc/hexane, giving after evaporation of the solvent and a swish in EtOAc, 10 g of the title compound.
- 30 Analysis calculated for $\text{C}_{17}\text{H}_{12}\text{F}_2\text{O}_4\text{S}$
C, 58.28; H, 3.45; S, 9.15
Found: C, 58.02; H, 3.51; S, 9.35

- 50 -

LACTONE 53-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
 Found: C, 58.18; H, 3.50; S, 9.44

LACTONE 6

10

3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
15 Found: C, 58.89; H, 3.51; S, 9.11

LACTONE 73-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

20 Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
 Found: C, 58.27; H, 3.62; S, 9.32

LACTONE 8

25

3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₃BrO₄S
 C, 51.94; H, 3.33; S, 8.16
30 Found: C, 51.76; H, 3.42; S, 8.21

- 51 -

LACTONE 93-(4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

- 5 ^1H NMR (300 MHz, CDCl_3) δ 7.93 (2H, d), 7.49 (2H, d), 7.35 (4H, m), 5.16 (2H, s), 3.06 (3H, s)

LACTONE 10

- 10 3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{18}\text{H}_{16}\text{O}_5\text{S}$

C, 62.78 H, 4.68; S, 9.31

Found: C, 62.75; H, 4.72; S, 9.39

15

LACTONE 113-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

- 20 Step 1: 2-Bromo-1-(4-(methylsulfonyl)phenyl)ethanone

To a solution of 197 g of 4-(methylthio)acetophenone (ref: JACS, 1952, 74, p. 5475) in 700 mL of MeOH and 3500 mL of CH_2Cl_2 was added 881 g of MMPP over a period of 30 min. After 3 hr at r.t. the reaction mixture was filtered and the filtrate was washed with 2 L of saturated aqueous solution of NaHCO_3 and 1 L of brine. The aqueous phase was further extracted with 2 L of CH_2Cl_2 . The combined extracts was dried over Na_2SO_4 concentrated to give 240 g of 4-(methylsulfonyl)acetophenone as a white solid.

- 25
30 To a cooled (-5°C) solution of 174 g of 4-(methylsulfonyl)acetophenone in 2.5 L of CHCl_3 was added 20 mg of AlCl_3 , followed by a solution of 40 mL of Br_2 in 300 mL CHCl_3 . The reaction mixture was then treated with 1.5 L of H_2O and the CHCl_3 was separated. The aqueous layer was extracted with 1 L of EtOAc. The combined extracts were dried over Na_2SO_4 and concentrated. The crude

- 52 -

product was recrystallized from 50/50 EtOAc/hexane to give 210 g of the title compound as a white solid.

Step 2:

5 To the product of Step 1 (216 mg) dissolved in acetonitrile (4 mL) was added Et₃N (0.26 mL), followed by 4-fluorophenylacetic acid (102 mg). After 1.5 hr at r.t., 0.23 mL of DBU was added. The reaction mixture was stirred for another 45 min. and then treated with 5 mL of 1N HCl. The product was extracted with EtOAc, dried over
10 Na₂SO₄ and concentrated. The residue was purified by flash chromatography (40% EtOAc in hexane) to yield 150 mg of the title compound as a solid.
1H NMR (CD₃COCD₃) δ 3.15 (3H, s), 5.36 (3H, s), 7.18 (2H, J=8.9 Hz, t), 7.46 (2H, m), 7.7 (2H, J=8.65 Hz, d), 7.97 (2H, J=8.68, d).

15

LACTONE 12

3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

20 Analysis calculated for C₁₇H₁₃ClO₄S
 C, 58.54; H, 3.76; S, 9.19
Found: C, 58.59; H, 3.80; S, 9.37

LACTONE 13

25

3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30 Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.75; H, 2.93
Found: C, 49.75; H, 3.01

- 53 -

LACTONE 14

3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

5

¹H NMR (300 MHz, acetone-d₆) δ 7.95 (2H, d), 7.85 (1H, d), 7.63 (2H, dd), 7.55 (1H, dd), 7.45 (1H, d), 5.50 (2H, s), 3.15 (3H, s)

LACTONE 15

10

3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.50-7.30 (3H, m), 5.35 (2H, s), 3.15 (3H, s)

15

LACTONE 16

3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

20

Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.75; H, 2.93

Found: C, 49.44; H, 2.98

25

LACTONE 17

3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30 Analysis calculated for C₁₇H₁₃ClO₄S
 C, 58.54; H, 3.76
Found: C, 58.29; H, 3.76

- 54 -

LACTONE 18

3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

5

Analysis calculated for C₁₇H₁₂ClFO₄S
 C, 55.67; H, 3.30
Found: C, 55.67; H, 3.26

10

LACTONE 19

3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

15

Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
Found: C, 52.89; H, 3.23; S, 8.58

LACTONE 20

20

3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
Found: C, 53.07; H, 3.32; S, 8.51

25

LACTONE 21

3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30

Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
Found: C, 52.99; H, 3.22; S, 8.54

- 55 -

LACTONE 22

3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

5

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.60 (1H, d), 7.25-7.40 (2H, m), 5.35 (2H, s), 3.15 (3H, s)

LACTONE 23

10

3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

¹H NMR (CD₃COCD₃) δ 8.10 (2H, d), 7.82-7.93 (4H, m), 7.75 (2H, d),
15 5.55 (2H, s), 3.30 (3H, s)

LACTONE 24

3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

20

Analysis calculated for C₁₈H₁₅FO₅S
 C, 59.66; H, 4.17

Found: C, 59.92; H, 4.37

25

LACTONE 25

3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

30

Analysis calculated for C₁₈H₁₅ClO₅S
 C, 57.07; H, 3.99

Found: C, 57.29; H, 4.15

- 56 -

LACTONE 26

3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

5

Analysis calculated for C₁₈H₁₅BrO₅S

C, 51.08; H, 3.57

Found: C, 51.38; H, 3.62

10

LACTONE 27

3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

Analysis calculated for C₁₇H₁₃FO₄S

15

C, 61.44; H, 3.94

Found: C, 61.13; H, 3.85

LACTONE 28

20 3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.35 (2H, d), 7.25 (2H, d), 5.35 (2H, s), 3.15 (3H, s), 2.55 (3H, s)

25

LACTONE 29

3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

¹H NMR (300 MHz, CDCl₃) δ 7.93 (2H, d), 7.49 (2H, d), 7.35 (1H, m),

30 7.12 (3H, m), 5.18 (2H, s), 3.06 (3H, s)

- 57 -

LACTONE 30

3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

5

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.55-7.65 (1H, m), 7.40 (1H, d), 7.30 (1H, m), 5.60 (2H, s), 3.15 (3H, s)

LACTONE 31

10

3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

Analysis calculated for C₁₈H₁₅BrO₄S
15 C, 53.08; H, 3.71
Found: C, 53.06; H, 3.83

LACTONE 32

20 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.65; H, 2.94
25 Found: C, 49.76; H, 3.00

LACTONE 33

3-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

30

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.80 (1H, d), 7.75 (3H, m), 7.25 (1H, d), 5.35 (2H, s), 3.15 (sH, s)

- 58 -

LACTONE 34

3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

5

Analysis calculated for C₁₇H₁₂ClFO₄S
 C, 55.67; H, 3.30
Found: C, 55.45; H, 3.30

10

LACTONE 35

3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

15 Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.66; H, 2.94; S, 7.80
Found: C, 49.79; H, 3.01; S, 7.51

LACTONE 36

20

3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

25 Analysis calculated for C₁₇H₁₂BrClO₄S
 C, 47.74; H, 2.83; S, 7.50
Found: C, 47.92; H, 2.84; S, 7.42

LACTONE 37

30 3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone

¹H NMR (400 MHz, CD₃COCD₃) δ 7.92 (2H, dd), 7.64 (3H, dm), 7.60 (1H, dd), 7.32 (1H, dd), 6.70 (1H, bs), 5.38 (2H, s)

- 59 -

LACTONE 383-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone

- 5 ^1H NMR (400 MHz, CD_3COCD_3) δ 7.92 (2H, dd), 7.64 (2H, dd), 7.30-7.45 (2H, m), 7.22 (1H, m), 6.68 (2H, bs), 5.37 (2H, s)

LACTONE 39

- 10 3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{17}\text{H}_{14}\text{ClNO}_5\text{S}$

C, 53.76; H, 3.72, N, 3.69

- 15 Found: C, 53.32; H, 3.84, N, 3.59

M.S. (DCI, CH_4) calculated for M^+ , 379

Found for M^++1 , 380

LACTONE 40

20

3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{17}\text{H}_{14}\text{BrNO}_5\text{S}$

- 25 C, 48.13; H, 3.33, N, 3.30

Found: C, 48.26; H, 3.40, N, 3.28

M.S. (DCI, CH_4) calculated for M^+ , 423

Found for M^++1 , 424

- 60 -

EXAMPLE 6 (Compound 10)

(Z)-2-(4-(METHYLSULFONYL)PHENYL)-3-(3,4-DIFLUOROPHENYL)-2-BUTENE-1,4-DIOL

5

A solution of DIBAL (185 mL, 1M in toluene) was added dropwise to a solution of Lactone 4 (20 g in 800 mL of THF) at 0°C. After stirring for 90 min at 0°C. and 18h at r.t., the mixture was recooled to 0°C and 100 mL of 1M sodium potassium tartrate was added dropwise. The product was extracted with ethyl acetate (200 mL) and dried over MgSO₄. Filtration and concentration provided the title compound (20 g) as a colorless syrup.

10

¹H NMR (acetone-d₆) δ 7.73 (2H, d), 7.38 (2H, d), 7.05 (2H, m), 6.85 (1H, m), 4.60 (4H, d), 4.10 (2H, br), 3.05 (3H, s).

15

EXAMPLE 7 (Compound 11)

(Z)-2-(4-(METHYLSULFONYL)PHENYL)-3-(3,4-DIFLUOROPHENYL)-2-BUTENE-1,4-DIOL 1-ACETATE

20

A solution of acetyl chloride (4.8 g) in CH₂Cl₂ (10 mL) was added dropwise to a solution of the diol from Example 10 (21.6 g), Et₃N (17.4 mL) and DMAP (1.0 g) in CH₂Cl₂ (2.0 L) at 0°C. After stirring for 15 min., 1N HCl (300 mL) was added and the organic layer separated, dried over MgSO₄ and concentrated. The residue was purified by flash chromatography using 1:1 EtOAc/toluene to afford 5.9 g of the title compound as a syrup followed by 5.9 g of its regioisomer also as a syrup.

25

30

¹NMR (acetone-d₆) δ 7.75 (2H, d), 7.37 (2H, d), 7.10 (2H, m), 6.85 (1H, m), 5.18 (2H, s), 4.62 (2H, d), 4.15 (1H, t), 3.05 (3H, s), 1.93 (3H, s).

- 61 -

EXAMPLE 8 (Compound 12)

(Z)-4-ACETOXY-3-(4-(METHYLSULFONYL)PHENYL)-2-(3,4-DIFLUOROPHENYL)-2-BUTENAL

5

A mixture of the acetate from Example 11 (5.4 g) and MnO₂ (4.3 g) in EtOAc was stirred for 18 h at r.t. and then filtered through a pad of celite. The filtrate was concentrated to give 3.6 g of the title compound as a yellow syrup.

10

¹H NMR (acetone-d₆) δ 10.52 (1H, s), 7.85 (2H, d), 7.52 (2H, d), 7.10 (2H, m), 6.78 (1H, m), 5.63 (2H, s), 3.05 (3H, s), 1.95 (3H, s).

15

EXAMPLE 9 (Compound 13a)

(Z)-4-ACETOXY-3-(4-METHYLSULFONYL)PHENYL)-2-(3,4-DIFLUOROPHENYL)-2-BUTENOIC ACID

20

To a solution of the aldehyde from Example 12 (3.6 g), 2-methyl-2-butene (36 mL), THF (54 mL), and t-BuOH (180 mL) was added a solution of NaClO₂ (7.3 g) and NaH₂PO₄ (8.6 g) in H₂O (108 mL). The mixture was stirred for 1h at r.t. The top organic layer was separated and concentrated. The residue was redissolved in EtOAc (50 mL), dried over MgSO₄, filtered and re-concentrated. The residue was purified by flash chromatography using 1:1 EtOAc/hexane containing 5% acetic acid to afford 1.3 g of the title compound, m.p. 133-134°C.

25

Analysis calculated for C₁₉H₁₆F₂SO₆

30

C, 55.60; H, 3.92; F, 9.25; S, 7.81

Found: C, 55.31; H, 4.00; F, 8.86; S, 8.04

- 62 -

EXAMPLE 10 (Compound 13b)

(Z)-4-ACETOXY-3-(4-(METHYLSULFONYL)PHENYL)-2-(3,4-DIFLUOROPHENYL) -2-BUTENOIC ACID SODIUM SALT

5

A mixture of the acid from Example 13a (1.18 g), NaHCO₃ (243 mg) and H₂O (75 mL) was sonicated for 30 min. and filtered through a cintered funnel to obtain a clear solution. The solution was frozen and lyophilized to afford 1.1 g of the title compound as a white powder.

10


¹H NMR (DMSO-d₆) δ 7.68 (2H, d), 7.28 (2H, d), 7.20 (1H, m), 7.10 (1H, m), 6.68 (1H, m), 5.08 (2H, s), 3.15 (3H, s), 1.85 (3H, s).

15

- 63 -

WHAT IS CLAIMED IS:

1. A compound of Formula I



5

I

or pharmaceutically acceptable salts thereof wherein

X is

10

- (a) CH₂OH,
- (b) CHO,
- (c) CO₂H, or
- (d) CO₂R⁴;

Y is

15

- (a) CH₂OH, or
- (b) CH₂OCOR⁵;

R¹ is selected from the group consisting of

20

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)(NH)CH₃,
- (e) S(O)(NH)NH₂,
- (f) S(O)(NH)NHC(O)CF₃,
- (g) P(O)(CH₃)OH, and
- (h) P(O)(CH₃)NH₂;

25

R² and R³ each are independently selected from the group consisting of

- (a) hydrogen,
- (b) halo,

- 64 -

- (c) C₁-6alkoxy,
(d) C₁-6alkylthio,
(e) CN,
(f) CF₃,
5 (g) C₁-6alkyl,
(h) N₃;

R⁴ is selected from the group consisting of

- (a) hydrogen, and
(b) C₁-6alkyl;

10 R⁵ is selected from the group consisting of

- (a) hydrogen,
(b) C₁-6alkyl,
(c) mono- or disubstituted phenyl wherein the substituent is
selected from

- 15 (1) hydrogen,
(2) halo,
(3) C₁-6alkyl,
(4) C₁-6alkoxy,
(5) C₁-6alkylthio,
20 (6) OH,
(7) CN,
(8) CF₃, and
(9) CO₂R⁴.

25 2. A compound according to Claim 1

X is

- (a) CH₂OH,
(b) CHO,
30 (c) CO₂H, or
(d) CO₂R⁴;

Y is

- (a) CH₂OH, or
(b) CH₂OCOR⁵;

- 65 -

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- 5 (d) S(O)(NH)CH₃,
- (e) S(O)(NH)NH₂, and
- (f) S(O)(NH)NHC(O)CF₃;

R² and R³ each are independently selected from the group consisting of

- (a) hydrogen,
- 10 (b) fluoro, chloro or bromo,
- (c) C₁-4alkoxy,
- (d) C₁-4alkylthio,
- (e) CN,
- (f) CF₃, and
- 15 (g) C₁-4alkyl;

R⁴ is selected from the group consisting of

- (a) hydrogen, and
- (b) C₁-4alkyl,

R⁵ is selected from the group consisting of

- 20 (a) hydrogen,
- (b) C₁-4alkyl,
- (c) mono- or disubstituted phenyl wherein the substituent is
selected from
 - (1) hydrogen,
 - 25 (2) halo,
 - (3) C₁-6alkyl,
 - (4) C₁-6alkoxy,
 - (5) OH, and
 - (6) CO₂R⁴.

30

3. A compound according to Claim 2 wherein:

X is

- (a) CH₂OH,

- 66 -

- (b) CHO,
- (c) CO₂H, or
- (d) CO₂R⁴;

Y is CH₂OH or CH₂OCOR⁵;

5 R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)NHCH₃,
- 10 (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃;

R² and R³ are each independently selected from the group consisting of

- (1) hydrogen,
- (2) fluoro, chloro, and bromo,
- 15 (3) C₁₋₄alkoxy,
- (4) C₁₋₄alkylthio,
- (5) CN,
- (6) CF₃,
- (7) C₁₋₄alkyl, and
- 20 (8) N₃.

R⁴ is selected from the group consisting of

- (a) hydrogen, and
- (b) C₁₋₄alkyl,

R⁵ is selected from the group consisting of

- 25 (a) hydrogen,
- (b) C₁₋₄alkyl,
- (c) mono- or disubstituted phenyl wherein the substituent is
selected from
- 30 (1) hydrogen,
- (2) halo,
- (3) C₁₋₆alky,
- (4) C₁₋₆alkoxy,
- (5) OH,
- (6) CO₂R⁴.

- 67 -

4. A compound according to Claim 3 wherein:

X is

- 5 (a) CH_2OH ,
(b) CHO , or
(c) CO_2H ,

Y is CH_2OH or CH_2OCOR^5 ; R^1 is selected from the group consisting of

- 10 (a) $\text{S}(\text{O})_2\text{CH}_3$,
(b) $\text{S}(\text{O})_2\text{NH}_2$,
(c) $\text{S}(\text{O})\text{NHCH}_3$,
(d) $\text{S}(\text{O})\text{NHNH}_2$, and

 R^2 and R^3 are each independently selected from the group consisting of

- 15 (1) hydrogen, and
(2) fluoro, chloro or bromo;

 R^4 is hydrogen; and R^5 is C_{1-3} alkyl.

5. A compound according to Claim 4 wherein:

20

X is

- (a) CH_2OH ,
(b) CHO , or
(c) CO_2H ;
25 Y is CH_2OH or CH_2OCOR^5 ;

 R^1 is selected from the group consisting of

- (a) $\text{S}(\text{O})_2\text{CH}_3$, and
(b) $\text{S}(\text{O})_2\text{NH}_2$,
30 R^2 and R^3 are each independently selected from the group consisting of
(1) hydrogen,
(2) fluoro, chloro or bromo;

 R^4 is hydrogen; and R^5 is C_{1-3} alkyl.

- 68 -

6. A compound according to claim 1 wherein:

X is CO_2R^4 ;

Y is CH_2OCOR^5 ,

R^1 is $\text{S}(\text{O})_2\text{CH}_3$;

5 R^2 and R^3 each are independently selected from the group consisting of

(a) hydrogen, and

(b) halo;

R^4 is selected from the group consisting of

(a) hydrogen, and

10 (b) C1-6alkyl;

R^5 is selected from the group consisting of

(a) C1-6alkoxy, and

(b) mono- or disubstituted phenyl wherein the substituent is
selected from

15 (1) hydrogen

(2) halo

(3) C1-6alkoxy

(4) OH.

20 7. A compound selected from the group consisting of

(a) (Z)-2-(4-(methylsulfonyl)phenyl)-3-phenyl-2-butene-1,4-
diol;

(b) (Z)-2-(4-(methylsulfonyl)phenyl)-3-phenyl-2-butene-1,4-
diol, 1-acetate;


25 (c) (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-phenyl
-2-butenal;

(d) (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-phenyl
-2-butenoic acid; and

30 (e) (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-phenyl-2-
butenoic acid, methyl ester.

- 69 -

8. A compound of formula Ia




Ia

wherein

R ²	R ³	Y	X
H	H	CH ₂ OH	CH ₂ OH
H	H	CH ₂ OH	CH ₂ OAc
H	H	CHO	CH ₂ OAc
H	H	CO ₂ H	CH ₂ OAc
H	H	CO ₂ Me	CH ₂ OAc
H	H	CH ₂ OH	CH ₂ OCOPh
H	H	CHO	CH ₂ OCOPh
H	H	CO ₂ H	CH ₂ OCOPh
H	H	CO ₂ Me	CH ₂ OCOPh
F	F	CH ₂ OH	CH ₂ OH
F	F	CH ₂ OH	CH ₂ OAc
F	F	CHO	CH ₂ OAc
F	F	CO ₂ H	CH ₂ OAc
F	F	CO ₂ Me	CH ₂ OAc
H	F	CH ₂ OH	CH ₂ OH
H	F	CH ₂ OH	CH ₂ OAc
H	F	CHO	CH ₂ OAc
H	F	CO ₂ H	CH ₂ OAc
H	F	CO ₂ Me	CH ₂ OAc

- 70 -

9. A compound of formula Ib



Ib

wherein

R^2	R^3	Y	X
H	H	CH ₂ OH	CH ₂ OH
H	H	CH ₂ OH	CH ₂ OAc
H	H	CHO	CH ₂ OAc
H	H	CO ₂ H	CH ₂ OAc
H	H	CO ₂ Me	CH ₂ OAc
H	H	CH ₂ OH	CH ₂ OCOPh
H	H	CHO	CH ₂ OCOPh
H	H	CO ₂ H	CH ₂ OCOPh
H	H	CO ₂ Me	CH ₂ OCOPh
F	F	CH ₂ OH	CH ₂ OH
F	F	CH ₂ OH	CH ₂ OAc
F	F	CHO	CH ₂ OAc
F	F	CO ₂ H	CH ₂ OAc
F	F	CO ₂ Me	CH ₂ OAc
H	F	CH ₂ OH	CH ₂ OH
H	F	CH ₂ OH	CH ₂ OAc
H	F	CHO	CH ₂ OAc
H	F	CO ₂ H	CH ₂ OAc
H	F	CO ₂ Me	CH ₂ OAc

- 71 -

10. A pharmaceutical composition for treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent comprising:
a non-toxic therapeutically effective amount of a compound according
5 to Claim 1, 2, 3, 4, 5 or 6 and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:
10 a non-toxic therapeutically effective amount of a compound according to Claim 1, 2, 3, 4, 5 or 6 and a pharmaceutically acceptable carrier.

12. A method of treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent comprising:
15 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.

13. A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively
20 inhibits COX-2 in preference to COX-1 comprising:
administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1.

14. A compound according to Claim 1 selected from the group consisting of:
25 (a) (Z)-2-(4-(methylsulfonyl)phenyl)-3-(3,4-difluorophenyl)-2-butene-1,4-diol,
(b) (Z)-2-(4-(methylsulfonyl)phenyl)-3-(3,4-difluorophenyl)-2-butene-1,4-diol, 1-acetate,

- 72 -

- (c) (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-(3,4-difluorophenyl)-2-butenal,
- (d) (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-(3,4-difluorophenyl)-2-butenic acid, and
- 5 (e) (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-(3,4-difluorophenyl)-2-butenic acid sodium salt.

15. A pharmaceutically acceptable salt of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5 or 6.

10 16. A non-steroidal anti-inflammatory pharmaceutical composition comprising an acceptable anti-inflammatory amount of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

15 17. A compound of formula (I), as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, for use in the treatment of inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.

20 18. Use of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1.


25 19. Use of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, as an anti-inflammatory agent.

-73-

AMENDED CLAIMS

[received by the International Bureau on 29 February 1996(29.02.96);
original claims 1 and 8 amended; remaining claims unchanged (3 pages)]

1. A compound of Formula I



5

I

or pharmaceutically acceptable salts thereof wherein

X is

10

- (a) CH₂OH,
- (b) CHO,
- (c) CO₂H, or
- (d) CO₂R⁴;

Y is

15

- (a) CH₂OH, or
- (b) CH₂OCOR⁵;

R¹ is selected from the group consisting of

20

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)(NH)CH₃,
- (e) S(O)(NH)NH₂,
- (f) S(O)(NH)NHC(O)CF₃,
- (g) P(O)(CH₃)OH, and
- (h) P(O)(CH₃)NH₂;

25

R² and R³ each are independently selected from the group consisting of

- (a) hydrogen,
- (b) halo,
- (c) C₁-6alkoxy,

-74-

- (d) C₁-6alkylthio,
(e) CN,
(f) CF₃,
(g) C₁-6alkyl,
5 (h) N₃;

R⁴ is selected from the group consisting of

- (a) hydrogen, and
(b) C₁-6alkyl;

R⁵ is selected from the group consisting of

- 10 (a) hydrogen,
(b) C₁-6alkyl,
(c) mono- or disubstituted phenyl wherein the substituent is
selected from
15 (1) hydrogen,
(2) halo,
(3) C₁-6alkyl,
(4) C₁-6alkoxy,
(5) C₁-6alkylthio,
(6) OH,
20 (7) CN,
(8) CF₃, and
(9) CO₂R⁴,

with the proviso that the compound is other than 2-(4-fluorophenyl)-3-
[(4-methylsulfonyl)phenyl]-1,4-dihydroxy-2-butene.

25

2. A compound according to Claim 1


X is

- (a) CH₂OH,
(b) CHO,
30 (c) CO₂H, or
(d) CO₂R⁴;

Y is

- (a) CH₂OH, or
(b) CH₂OCOR⁵;

8. A compound of formula Ia



Ia

wherein

<u>R²</u>	<u>R³</u>	<u>Y</u>	<u>X</u>
H	H	CH ₂ OH	CH ₂ OH
H	H	CH ₂ OH	CH ₂ OAc
H	H	CHO	CH ₂ OAc
H	H	CO ₂ H	CH ₂ OAc
H	H	CO ₂ Me	CH ₂ OAc
H	H	CH ₂ OH	CH ₂ OCOPh
H	H	CHO	CH ₂ OCOPh
H	H	CO ₂ H	CH ₂ OCOPh
H	H	CO ₂ Me	CH ₂ OCOPh
F	F	CH ₂ OH	CH ₂ OH
F	F	CH ₂ OH	CH ₂ OAc
F	F	CHO	CH ₂ OAc
F	F	CO ₂ H	CH ₂ OAc
F	F	CO ₂ Me	CH ₂ OAc
H	F	CH ₂ OH	CH ₂ OAc
H	F	CHO	CH ₂ OAc
H	F	CO ₂ H	CH ₂ OAc
H	F	CO ₂ Me	CH ₂ OAc

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 95/00601

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C317/22 C07C317/24 C07C317/46 C07C311/29 C07C311/51
C07C311/49 C07F9/30 C07F9/36 A61K31/10 A61K31/18
A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,5 344 991 (D.B. REITZ, ET AL.) 6 September 1994 see column 1 - column 2 ---	1,10
A	EP,A,0 424 541 (OTSUKA PHARMACEUTICAL FACTORY) 2 May 1991 cited in the application see page 2 ---	1
A	JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no. 18, September 1984 LETCHWORTH, GB, pages 1234-1235, F. TODA, ET AL.: 'A new preparative method for (E)-2,3-diarylbut-2-enedials' cited in the application see compounds 5a, 5b, 8 --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

12 January 1996

Date of mailing of the international search report

19.01.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 95/00601

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 88, no. 6, 20 March 1966 WASHINGTON, DC, US, pages 1289-1292, J. TSUJI, ET AL.: 'Organic synthesis by means of noble metal compounds. XXII. Palladium-catalysed carbonylation of diphenylacetylene' cited in the application see compound VI ---	1
A	JOURNAL OF ORGANIC CHEMISTRY, vol. 45, no. 5, 29 February 1980 WASHINGTON, DC, US, pages 922-924, K.L. DHAWAN, ET AL.: 'Preparation of benzocyclobutenols from o-halostyrene oxides' cited in the application see compound 5 ---	1
P,X	US,A,5 393 790 (D.B. REITZ, ET AL.) 28 February 1995 see column 56, line 14 - line 37 ---	1
P,A	see column 1 - column 2 ---	1,10
P,A	WO,A,95 00501 (MERCK FROSST CANADA) 5 January 1995 see page 3 - page 7; examples 9,10,15-54 -----	1,10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA95/00601

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12, 13 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 95/00601

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5344991	06-09-94	AU-B- 7365094 WO-A- 9511883 US-A- 5420287	22-05-95 04-05-95 30-05-95
EP-A-424541	02-05-91	AU-B- 625123 AU-B- 5435690 WO-A- 9012786 US-A- 5082974	02-07-92 16-11-90 01-11-90 21-01-92
US-A-5393790	28-02-95	AU-B- 1740895 WO-A- 9521817	29-08-95 17-08-95
WO-A-9500501	05-01-95	US-A- 5474995 AU-B- 1269495 AU-B- 6967494 WO-A- 9518799	12-12-95 01-08-95 17-01-95 13-07-95